Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.30 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2498595 | 0.75 | CYP17A1 (0.38) | HSP90AA1ADORA2AADORA1LOXL2PDPK1 | |
| SCHEMBL1033845 | 0.75 | NPC1 (0.43) | ADORA2AADORA1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL1021932 | 0.75 | ADORA2A (0.50) | HSP90AA1ADORA2AADORA1ALDH1A1TSHR | |
| SCHEMBL2493845 | 0.73 | HSP90AA1 (0.40) | HSP90AA1ADORA2AADORA1ALDH1A1TSHR | |
| SCHEMBL1023706 | 0.66 | CHRM4 (0.35) | HSP90AA1ADORA2AADORA1LOXL2PDPK1 | |
| SCHEMBL5017807 | 0.64 | ADORA2A (0.49) | HSP90AA1ADORA2AADORA1ALDH1A1TSHR | |
| SCHEMBL18675868 | 0.63 | HSP90AA1 (0.47) | HSP90AA1ADORA2AADORA1ALDH1A1TSHR | |
| SCHEMBL5157931 | 0.62 | ALDH1A1 (0.43) | HSP90AA1ADORA2AADORA1ALDH1A1TSHR | |
| SCHEMBL1489975 | 0.62 | HSP90AA1 (0.54) | HSP90AA1ADORA2AADORA1ALDH1A1TSHR | |
| SCHEMBL2489977 | 0.60 | PDPK1 (0.52) | HSP90AA1ADORA2AADORA1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1970445-B1 | METHOD FOR NUCLEIC ACID REPLICATION AND NOVEL ARTIFICIAL BASE PAIRS | RIKEN (JP) | 2012-09-26 | — | — | EP | claimed |
| US-8030478-B2 | Method for nucleic acid replication and novel artificial base pairs | RIKEN (JP) | 2011-10-04 | — | — | US | claimed |
| US-20100036111-A1 | METHOD FOR REPLICATING NUCLEIC ACIDS AND NOVEL UNNATURAL BASE PAIRS | RIKEN (JP) | 2010-02-11 | — | — | US | claimed |
| EP-1970445-A1 | METHOD FOR NUCLEIC ACID REPLICATION AND NOVEL ARTIFICIAL BASE PAIRS | Riken (JP) | 2008-09-17 | — | — | EP | claimed |
| EP-1970445-B1 | METHOD FOR NUCLEIC ACID REPLICATION AND NOVEL ARTIFICIAL BASE PAIRS | RIKEN (JP) | 2012-09-26 | — | — | EP | disclosed |
| US-8030478-B2 | Method for nucleic acid replication and novel artificial base pairs | RIKEN (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20100036111-A1 | METHOD FOR REPLICATING NUCLEIC ACIDS AND NOVEL UNNATURAL BASE PAIRS | RIKEN (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-1970445-A1 | METHOD FOR NUCLEIC ACID REPLICATION AND NOVEL ARTIFICIAL BASE PAIRS | Riken (JP) | 2008-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036111-A1 | METHOD FOR REPLICATING NUCLEIC ACIDS AND NOVEL UNNATURAL BASE PAIRS | POLM, POLL, POLRMT | HSP90AA1 2668/4885ADORA2A 978/4885ADORA1 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.